FOxTROT Trial Overview

Document Sample
FOxTROT Trial Overview Powered By Docstoc
					                              FOxTROT - Fluoropyrimidine, Oxaliplatin and Targeted Receptor
                              pre-Operative Therapy for high risk colon cancer
                              Protocol Development Group: Dion Morton, Gina Brown, David Ferry, Richard Gray, Laura Magill, Phil Quirke,
                              Matt Seymour, Bryan Warren


FOXTROT trial objectives:                                                                  Panitumumab in FOxTROT                                                          Eligibility criteria
►FOxTROT is a Multi-centre RCT to determine:                                               • Data from the OPUS and CRYSTAL trials showed that anti-EGFR                   Exclusion criteria:
                                                                                           monoclonal antibodies are effective only in patients with wildtype K-Ras               • Rectal tumours
                                                                                           expression                                                                             • Distant metastases
   • Whether giving the 1st 6 weeks of chemotherapy pre-operatively compared
                                                                                                                                                                                  • Serious medical morbidity
   with the standard 24-weeks post-operatively reduces the risk of disease                 • ~ 60% colorectal cancers are WT for K-Ras expression
   recurrence at 2 years?
                                                                                           • All patients will be screened at trial entry for K-Ras expression

   • Whether adding panitumumab to preoperative chemotherapy of KRAS                       • Tumour analysis available within 1 week
   wildtype tumours produces a measurable increase in anti-tumour efficacy as              • K-Ras WT tumours randomised across all 4 arms of the trial
   measured by tumour shrinkage.
                                                                                                                                                                          Trial design                          A) OxMdG                       OxMdG
                                                                                                                                                                                                                                   S                      A
                                                                                           • K-Ras mutant tumours NOT eligible for p-mab, randomised between pre-                                                   x3                           x9
                                                                                                                                                                                                                                   U
                                                                                           plus post-op vs post-op chemotherapy only.                                                                             (6wks  )
                                                                                                                                                                                                                                             (18 weeks)
                                                                                                                                                                                                                                   R
                                                                                           • Centres can elect to not randomise into the panitumumab arms of                                                      B) OxMdG         G           OxMdG
Rationale behind the trial                                                                 FOxTROT                                                                        Operable                                    x3           E             x9       B
                                                                                                                                                                        Colon Cancer                                (6wks)         R         (18 weeks)
   • Neoadjuvant therapy has been shown to improve success rates in:                                                                                                                                                               Y
                                                                                                                                                                        T4 or high risk
      -   rectal cancer, stomach cancer, oesophageal cancer                                                                                                                T3 by CT                             Pan (6wks)
                                                                                                                                                                                            Randomise
                                                                                                           FOxTROT Randomisation Pathway                                    criteria;
   • Improvements in chemotherapy for colorectal cancer:                                                                                                                Fit for surgery
                                                                                                                                                                                                               S                   C) OxMdG x12           C
       -    Fluoropyrimidine/Oxaliplatin chemotherapy achieves high                                Introduce FOxTROT idea                                                and chemo                                                  (24 weeks)
                                                                                                                                                                                                               U
       (> 50%) response in advanced disease De Gramont                                            Obtain consent for K-RAS test
                                                                                                                                                                                                               R
       -     Low risk of progression during chemotherapy (14% at 12                               Give patient FOxTROT P.I.S.                  Fax consent form to
                                                                                                                                                                                                               G                   D) OxMdG x12
   weeks in FOCUS)                               Seymour ASCO 2005                                                                               pathology dept                                                                                           D
                                                                                                                                                                                                               E                    (24 weeks)
                                                                                                      Min 24 hr
       -     Short (6-week) pre-operative course, toxicity acceptable &                                                                                                                                        R               Pan
   unlikely to delay surgery                     André NEJM 2004                                                                                                                                               Y             (6wks)
                                                                                                  Obtain consent for FOxTROT                  Send biopsy block to
      -   Panitumumab shown to be effective in patients with wildtype                             Optional consent for ± P-mab                FOxTROT Trial Lab
   KRAS tumours                             Van Cutsem ASCO 2008                               Randomise for pre vs post-op OxMdG
                                                                                                        Give main P.I.S   .


   • Improved CT scan staging                                                                                                               Send KRAS test result to    Primary Outcome
       -  Pilot cohort study of 102 scans, 2 independent, blinded                                                    Fax test result &       FOxTROT study office
                                                                                                                     allocation to key                                     • Disease free recurrence at 2 years
   observers                                                                                         Usually ≥7
       -  distinguished low risk from high risk                                                      days                worker &                                                 – pre+post-op vs post-op therapy (A+B vs C+D)
       -  only 1 (T2) over-staged                   G Brown, I Swift                                                     pharmacy              If KRAS wildtype &
                                                                                                                                              consent, randomise to
                                                                                                                                                    ± P-mab                • Impact of panitumumab on tumour down-staging
                                                                                                    Start FOxTROT treatment
                                                                                                         (chemotherapy ±                                                          - pathological depth of extramural invasion (A vs B)
                                                                                                    panitumumab or surgery)
FOxTROT – 2 stage trial
                                                                                                                                                                       Trial status
 Pilot stage – 150 patients will be randomised and will be used to:
                                                                                                                                                                         • FOXTROT has been funded by CRUK and approved by the West Glasgow MREC
      • Establish safety & tolerability of neoadjuvant therapy
                                                                                                                                                                         • 14 centres fully open to recruitment
      • Validate & fine-tune radiological staging criteria                             Eligibility criteria
      • Only OxMdG will be prescribed in the pilot phase                                                                                                                          - A further 61 centres signed up and awaiting approval
                                                                                       Inclusion criteria:
                                                                                                                                                                                  - 5 radiology and 2 pathology training days held so far
                                                                                             • Histologically proven colon cancer
 Phase III – Additional 900 patients will be randomised:                                     • CT scan indicating poor prognosis:                                                 - TRICC application funded
      • Panitumumab arm retention if safe and tolerated in pilot                                    - T4 or T3 ‘bad’ tumours                                                      - Radiology audit in place at selected centres
      • Implement standardised radiological staging and histology                                   (T3 bad = depth of invasion ≥5mm muscularis propria)                 Contact trial coordinator, Dr Laura Magill, to sign up:
reporting                                                                                           - NX, M0
                                                                                                                                                                                          e.l.magill@bham.ac.uk Tel: 0121 415 9105
                                                                                             • Patients presenting with acute colonic obstruction if successfully
                                                                                             defunctioned



                                                                 FOxTROT was developed by the NCRI Colorectal Cancer Clinical Study Group and is funded by Cancer Research UK

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:37
posted:6/12/2012
language:English
pages:1